Novo Nordisk, Wegovy and obesity

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned ...
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...